Clinical Trials

UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.

For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email cancerclinicaltrials@virginia.edu.

 

 

 

New Trials Available at UVA

Breast Oncology (IRB-HSR #20518)

Single-Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable, Locally-Advanced or Metastatic Triple-Negative Breast Cancer (NCT03310957)

Primary Investigator: Patrick Dillon

Clinical Research Coordinator: Jake Boyd

Breast Oncology (IRB-HSR #20295)

Randomized and Blinded Clinical Evaluation of DermACELL Without Basement Membrane in Breast Reconstruction

Primary Investigator: Patrick Cottler

Clinical Research Coordinator: Dena Synyder

Genitourinary Oncology (IRB-HSR #20610)

ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (NCT03397394)

Primary Investigator: Robert Dreicer

Clinical Research Coordinator: Julio Torres

Hematologic Malignancies (IRB-HSR #20613)

A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens

Primary Investigator: Laahn Foster
Clinical Research Coordinators: Michal Ande

Hematologic Malignancies (IRB-HSR #20729)

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Primary Investigator: Craig Portell
Clinical Research Coordinator: Amelia Hodson, Kristen L. Johnson

Hematologic Malignancies

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Primary Investigator: Karen Ballen
Clinical Research Coordinator: Amelia Hodson

Thoracic Oncology (IRB-HSR #20704)

A Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced squamous or non-squamous NSCLC and previous clinical benefit on treatment with a PD-1 or PD-L1 inhibitor (NCT03041181)

Primary Investigator: Richard Hall
Clinical Research Coordinator: Gracie Tubbs Hockenberry

Idiopathic Parkinson’s Disease (IRB-HSR #180001)

A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System (NCT03319485)

Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson

Idiopathic Parkinson’s Disease (IRB-HSR #17552)

A Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System

Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson

Chronic Trigeminal Neuropathic Pain (IRB-HSR #170004)

A Feasibility Study of Focused Ultrasound to Perform Bilateral Medial Thalamotomy for the Treatment of Chronic Trigeminal Neuropathic Pain (NCT03309813)

Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson

Newly Diagnosed Glioblastoma (IRB-HSR #19800)

INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT). (NCT02977780)

Primary Investigator: David Schiff
Clinical Research Coordinator: Starlene Truslow

Newly Diagnosed Glioblastoma (IRB-HSR #20105)

A Phase I Study Targeting Newly Diagnosed Glioblastoma with anti-CD3 x anti-EGFR Bispecific Antibody Armed T cells (EGFR BATs) in Combination with Radiation and Temozolomide (NCT03344250)

Primary Investigator: Camilo Fadul
Clinical Research Coordinator: Melissa Otoya

Newly Diagnosed & Recurrent Glioblastoma (IRB-HSR #170002)

A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma (NCT03150862)

Primary Investigator: David Schiff
Clinical Research Coordinator: Carol Woodburn